Double Bottom with Handle? EQ has formed a double bottom on the daily chart and now working on the handle with possible accumulation.
0A4D trade ideas
EQ Watch for Resistance Breakout. Bullish FridayEQ reached top mover status as a gainer one day and a loser the following day.
Thursday, EQ was up +1.49% pre-market.
I predict stock moves at a steady pace toward $24 price target.
EQ is a mall biotech company researching Alzheimer's medicine.
Healthcare is our third-largest sector ($6.2 T).
Financials ($7.53 T) ranks second and information technology ($9.58 T) first.
Please always do your own research.
This is not advice.
I'm here to learn.
Thoughts?
EQ, a top quarterly gainer, rising +795%.Expect Uptrend reversalEquillium (EQ, $26.5) was one of top quarterly gainers, jumping +795.27% to $26.5 per share. Tickeron A.I.dvisor analyzed 383 stocks in the Biotechnology Industry over the last three months, and discovered that 298 of them (77.69%) charted an Uptrend while 85 of them (22.31%) trended down. Tickeron A.I.dvisor found 51 similar cases when EQ's price went up 15% within three months. In 51 out of those 51 cases, EQ's price went down during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend reversal for EQ are 90%.
The higher Bollinger Band was broken -- a price fall is expected as the ticker heads toward the middle band, which invites the trader to consider selling or shorting the ticker, or exploring put options. Tickeron AI shows that in 13 of 13 cases where EQ's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 90%.
The Aroon Indicator entered a Downtrend today.Tickeron AI shows that in 33 of 42 cases where EQ Aroon's Indicator entered a Downtrend, the price fell further within the following month. The odds of a continued Downtrend are 79%.
Itolizumab Reduces Mortality in Patients Hospitalized with COVIDClinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon
Biocon has received emergency use approval from Drugs Controller General of India for itolizumab in the treatment of CRS in COVID-19 patients with moderate to severe ARDS
Equillium planning global randomized controlled clinical trial of itolizumab in COVID-19 patients under a U.S. IND
www.globenewswire.com
it is bought with the rumor and it is sold with the news #EQequillium EQ-explodes-730%-positive-covid
it is bought with the rumor and it is sold with the news
“We note the trial in hospitalized COVID-19 patients was small (n=30), open-label and on top of standard of care, and little data were shared but according the Biocon/EQ press releases, the itolizumab arm did demonstrate a statistically significant benefit on mortality at one-month (the primary endpoint)” he told investors.
The results of this clinical trial reported by Biocon are encouraging and support the hypothesis that itolizumab’s novel immune-modulating mechanism may have promise in addressing the severe immuno-inflammatory complications experienced by COVID-19 patients,” said Bruce Steel, CEO of Equillium.
